Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gisle Langslet

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Journal of Clinical Lipidology|October 16, 2018
Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT studyDaniel Gaudet, Gisle Langslet, Samuel S Gidding, et al.
Atherosclerosis|December 10, 2020
Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from ScandinaviaKarianne Svendsen, Gisle Langslet, Henriette W Krogh, et al.
Diabetes Care|September 11, 2014
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 studyLawrence A Leiter, Kun-Ho Yoon, Pablo Arias, et al.
Journal of Clinical Lipidology|March 27, 2019
LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemiaMartin P Bogsrud, Asgeir Græsdal, Dan Johansen, et al.
The American Journal of Cardiology|February 24, 2018
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials)Peter A McCullough, Christie M Ballantyne, Santosh K Sanganalmath, et al.
Atherosclerosis|February 18, 2014
Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatmentKirsten B Holven, Ingunn Narverud, Henriette W Lindvig, et al.
Journal of Clinical Lipidology|April 11, 2017
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemiaJohn J P Kastelein, G Kees Hovingh, Gisle Langslet, et al.
JAMA Cardiology|March 15, 2017
Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension StudyMichael J Koren, Marc S Sabatine, Robert P Giugliano, et al.
Journal of the American College of Cardiology|March 13, 2010
Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemiaHans J Avis, Barbara A Hutten, Claude Gagné, et al.
Journal of Clinical Lipidology|July 28, 2012
Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemiaAsgeir Græsdal, Martin Prøven Bogsrud, Kirsten Bjørklund Holven, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Journal of Clinical Lipidology|October 16, 2018
Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT studyDaniel Gaudet, Gisle Langslet, Samuel S Gidding, et al.
Atherosclerosis|December 10, 2020
Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from ScandinaviaKarianne Svendsen, Gisle Langslet, Henriette W Krogh, et al.
Diabetes Care|September 11, 2014
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 studyLawrence A Leiter, Kun-Ho Yoon, Pablo Arias, et al.
Journal of Clinical Lipidology|March 27, 2019
LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemiaMartin P Bogsrud, Asgeir Græsdal, Dan Johansen, et al.
The American Journal of Cardiology|February 24, 2018
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials)Peter A McCullough, Christie M Ballantyne, Santosh K Sanganalmath, et al.
Atherosclerosis|February 18, 2014
Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatmentKirsten B Holven, Ingunn Narverud, Henriette W Lindvig, et al.
Journal of Clinical Lipidology|April 11, 2017
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemiaJohn J P Kastelein, G Kees Hovingh, Gisle Langslet, et al.
JAMA Cardiology|March 15, 2017
Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension StudyMichael J Koren, Marc S Sabatine, Robert P Giugliano, et al.
Journal of the American College of Cardiology|March 13, 2010
Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemiaHans J Avis, Barbara A Hutten, Claude Gagné, et al.
Journal of Clinical Lipidology|July 28, 2012
Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemiaAsgeir Græsdal, Martin Prøven Bogsrud, Kirsten Bjørklund Holven, et al.
Pageof 6